Hematologic and cytogenetic responses in bosutinib trials.
Stage of disease . | CHR, % (n) . | MCyR, % (n) . | CCyR, % (n) . |
---|---|---|---|
Abbreviations: CHR, complete hematologic response; CCyR, complete cytogenetic response; MCyR, major cytogenetic response; n, number evaluable; TKi, tyrosine kinase inhibitor. | |||
Chronic phase24 | |||
Exposed to imatinib only | 89 (38) | 41 (56) | 36 (56) |
Exposed to imatinib and other TKIs | 77 (13) | 20 (10) | — — |
Accelerated phase25 | |||
Exposed to imatinib only | 50 (8) | 44 (9) | 22 (9) |
Exposed to imatinib and other TKIs | 11 (9) | 0 (6) | 0 (6) |
Blast crisis25 | |||
Exposed to imatinib only | 15 (13) | 18 (11) | 9 (11) |
Exposed to imatinib and other TKIs | 7 (14) | 20 (10) | 20 (10) |
Stage of disease . | CHR, % (n) . | MCyR, % (n) . | CCyR, % (n) . |
---|---|---|---|
Abbreviations: CHR, complete hematologic response; CCyR, complete cytogenetic response; MCyR, major cytogenetic response; n, number evaluable; TKi, tyrosine kinase inhibitor. | |||
Chronic phase24 | |||
Exposed to imatinib only | 89 (38) | 41 (56) | 36 (56) |
Exposed to imatinib and other TKIs | 77 (13) | 20 (10) | — — |
Accelerated phase25 | |||
Exposed to imatinib only | 50 (8) | 44 (9) | 22 (9) |
Exposed to imatinib and other TKIs | 11 (9) | 0 (6) | 0 (6) |
Blast crisis25 | |||
Exposed to imatinib only | 15 (13) | 18 (11) | 9 (11) |
Exposed to imatinib and other TKIs | 7 (14) | 20 (10) | 20 (10) |